Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
requires medical knowledge to minimize risk Intranasal Intranasal delivery to target the olfactory bulb and trans-cribriform access to the brain has been explored for some peptides: Theoretical advantage: Direct CNS access, bypassing the blood-brain barrier Reality: Intranasal peptide formulations are complex and Dihexa is not commonly available in this form Evidence: No published data on intranasal Dihexa efficacy or safety Oral Bioavailability: Approximately 38% The most commonly cited bioavailability figure for oral Dihexa is approximately 38%
Any decision about which molecule, if either, is appropriate must be made with a qualified healthcare professional who can account for individual physiology, contraindications, and local law
Repatha is a PCSK9 inhibitor that works by increasing the number of LDL receptors on the liver to clear more cholesterol from the blood
The problem with DPL is its minimal BBB permeability and increase in the dose frequency leads to significant cholinergic adverse effects
P.YangD.FitzpatrickE.VogelP.et al (2021)
